Addressing the Role of PARP Inhibitors in Different Breast Cancer Settings
April 10th 2018Jennifer Litton, MD, associate professor in the Department of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center, discusses her opinion on the use of PARP inhibitors in the field of breast cancer.
Watch
An Expert's Thoughts on the FDA Approval of Durvalumab in Locally Advanced Lung Cancers
April 9th 2018Mark G. Kris, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the recent FDA approval of durvalumab (Imfinzi) for the treatment of patients with locally advanced, unresectable stage III non–small cell lung cancer.
Watch
Recognizing Immunotherapy Side Effects in the Community Setting
April 9th 2018David M. Nanus, MD, chief of the Division of Hematology and Medical Oncology at Weill Cornell Medicine, discusses the use of immunotherapy in the community setting. He also gives advice to community oncologists that are using these treatments in their practice. <br />
Watch